Hypothesis

Aged immune cells export mitochondrial ROS‑laden extracellular vesicles (EVs) that deliver oxidative mtDNA and oxidized lipids to hematopoietic stem cells (HSCs). This transfer induces epigenetic rewiring—specifically, loss of H3K27me3 at promoters of myeloid‑biased genes and gain of H3K4me3 at inflammatory cytokine loci—thereby skewing HSC output toward pro‑inflammatory myeloid lineages and fostering clonal hematopoiesis of indeterminate potential (CHIP). The resulting influx of inflammatory monocytes/macrophages amplifies inflammaging and SASP production in peripheral tissues, creating a self‑reinforcing loop where immune‑derived EVs both cause and exacerbate HSC dysfunction.

Mechanistic Rationale

1. Mitochondrial ROS as EV cargo – Senescent T cells and macrophages exhibit heightened mitochondrial ROS that oxidizes mtDNA and lipids, which are selectively packaged into EVs (exosomes and microvesicles) [7].
2. EV uptake by HSCs – Circulating EVs preferentially bind to HSCs via phosphatidylserine receptors, delivering oxidized mtDNA that activates cytosolic cGAS‑STING signaling, leading to NF‑κB activation and downstream epigenetic modifiers (e.g., DNMT3A, TET2) [2].
3. Epigenetic re‑programming – Chronic cGAS‑STING/NF‑κB signaling recruits histone‑acetyltransferases (p300/CBP) to myeloid gene promoters while recruiting PRC2 antagonists to lymphoid loci, locking in a myeloid‑biased transcriptional program [5].
4. Clonal expansion – Epigenetically primed HSCs exhibit increased self‑renewal and myeloid differentiation, providing a selective advantage for clones harboring somatic mutations in DNMT3A, TET2, or JAKV617F, thus accelerating CHIP [3].
5. Feedback to tissues – Expanded myeloid progeny secrete IL‑6, TNF‑α, and IL‑1β, reinforcing SASP in senescent parenchyma and further stimulating immune‑cell ROS production, completing the loop [1][4].

Testable Predictions

• Prediction 1: Pharmacological inhibition of mitochondrial ROS in aged T cells (e.g., with MitoTEMPO) will reduce EV mtDNA oxidation and decrease HSC uptake of oxidized mtDNA in vivo.
• Prediction 2: HSCs isolated from mice treated with EV‑release inhibitors (GW4869) will show preserved lymphoid potential and reduced myeloid bias, even in an aged environment.
• Prediction 3: Adoptive transfer of EVs from ROS‑high aged T cells into young mice will accelerate acquisition of myeloid‑biased epigenetic marks and increase CHIP‑like clones within 4 weeks.
• Prediction 4: Blocking cGAS‑STING in HSCs will attenuate EV‑induced NF‑κB signaling and prevent myeloid skewing, despite the presence of aged immune EVs.

Experimental Approach

1. Isolate EVs from splenic T cells of young (3 mo) and aged (24 mo) mice; quantify mtDNA oxidation (8‑OH‑dG) and lipid peroxidation (MDA) by ELISA.
2. Label EVs with fluorescent dyes and inject intravenously into young recipients; track HSC uptake via flow cytometry (Lin⁻Sca‑1⁺c‑Kit⁺).
3. Assess epigenetic changes in sorted HSCs using ATAC‑seq and ChIP‑seq for H3K27me3/H3K4me3 at myeloid (Cebpa, Mpo) and lymphoid (Il7r, Rag1) loci.
4. Functional assays: competitive bone‑marrow transplantation to measure myeloid vs. lymphoid output; clonal tracking via barcode sequencing to detect expansion of mutant clones.
5. Intervention groups: MitoTEMPO treatment, GW4869 EV‑release inhibition, and cGAS‑STING knockout (cGAS⁻/⁻) in HSCs; compare to controls.

Implications

If validated, this hypothesis shifts the focus from systemic inflammation alone to a specific immune‑to‑stem‑cell communication pathway mediated by oxidative EVs. Therapeutically, targeting mitochondrial ROS in immune cells, inhibiting EV release, or blocking cGAS‑STING in HSCs could break the vicious cycle, preserving hematopoietic youth and delaying multisectorial aging. It also provides a mechanistic link between immunosenescence, CHIP, and tissue‑level inflammaging, offering a unified framework for interventions that extend healthspan by rescuing immune surveillance at its source.